股本结构
单位：万股
| 公告日期 | 2026-08-12 | 2026-04-29 | 2026-05-15 | 2026-02-11 | 2026-04-15 | 2025-11-19 |
|---|---|---|---|---|---|---|
| 证券总股本 | 818.98 | 785.34 | 785.34 | 785.34 | 769.04 | 416.68 |
| 普通股本 | 818.98 | 785.34 | 785.34 | 785.34 | 769.04 | 416.68 |
| 优先股 | 8.49 | 8.49 | 8.49 | 7.61 | 8.49 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2026-06-30 | 2026-04-26 | 2026-03-31 | 2026-02-10 | 2025-12-31 | 2025-11-17 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2026-08-12 | 818.98 | 8.49 |
更多>>
From March 31,2026 to June 30,2026
Stock based compensation - Restricted Stock Awards
Stock-based Compensation - Restricted Stock Units
Preferred Stock Dividends and Dividend Adjustments
|
2026-06-30 |
| 2026-04-29 | 785.34 | 8.49 | 定期报告 | 2026-04-26 |
| 2026-05-15 | 785.34 | 8.49 |
更多>>
From December 31, 2025 to March 31, 2026
Common Stock Warrant Exercises
Stock based compensation – Restricted Stock Units
|
2026-03-31 |
| 2026-02-11 | 785.34 | 7.61 | 定期报告 | 2026-02-10 |
| 2026-04-15 | 769.04 | 8.49 |
更多>>
From December 31, 2024 to December 31, 2025
True-up for par value related to reverse stock split
Issuance of Series G Convertible Preferred Stock in Lieu of Dividends
Issuance of 7,000 shares of Series H Convertible Preferred Stock, net of discount and offering costs of $609,578
Issuance of 747,362 shares of Series I Convertible Preferred Stock
Conversion of 1,946 shares of Series G Convertible Preferred Stock
Conversions of Series H Convertible Preferred Stock
Conversions of Series I Convertible Preferred Stock
Conversion of Series F and F1 Convertible Preferred Stock
Issuance of Common Stock for Services Provided
Issuance of Common Stock as Series H Dividends
Common Stock Warrant Exercises
|
2025-12-31 |
| 2025-11-19 | 416.68 | 未披露 | 定期报告 | 2025-11-17 |
| 2025-11-19 | 297.77 | 8.88 |
更多>>
From June 30, 2025 to September 30, 2025
Accelerated Conversion of 4,382 shares of Series F Convertible Preferred Stock
Accelerated Conversion of 2,065 shares of Series F-1 Convertible Preferred Stock
Conversion of 606 shares of Series G Convertible Preferred Stock
Issuance of Series G Convertible Preferred Stock
Issuance of 7,000 shares of Series H Convertible Preferred Stock, net of discount and offering costs of $609,578
Issuance of 747,362 shares of Series I Convertible Preferred Stock
Proceeds from the exercise of common stock warrants
|
2025-09-30 |
| 2025-10-20 | 205.30 | 83.65 | 定期报告 | 2025-09-18 |
| 2025-09-10 | 184.69 | 未披露 | 定期报告 | 2025-09-03 |
| 2025-08-28 | 178.62 | 未披露 |
更多>>
a reverse stock split of the Company's common stock at a ratio of 1 post-split share for every 100 pre-split shares
|
2025-09-02 |
| 2025-09-02 | 17861.57 | 未披露 | 定期报告 | 2025-08-27 |
| 2025-08-19 | 17661.57 | 未披露 | 定期报告 | 2025-08-18 |
| 2025-08-19 | 2938.37 | 8.82 |
更多>>
From March 31, 2025 to June 30, 2025
Accelerated Conversion of 24 shares of Series F Convertible Preferred Stock
Accelerated Conversion of 1,748 shares of Series F-1 Convertible Preferred Stock
Conversion of 1,021 shares of Series G Convertible Preferred Stock
|
2025-06-30 |
| 2025-05-15 | 1418.41 | 未披露 | 定期报告 | 2025-05-13 |
| 2025-04-11 | 1013.26 | 未披露 | 定期报告 | 2025-04-04 |
| 2025-05-15 | 739.26 | 8.88 |
更多>>
From December 31, 2024 to March 31, 2025
Accelerated Conversion of 371 shares of Series F Convertible Preferred StockAccelerated Conversion of 2001 shares of Series F-1 Convertible Preferred Stock
Conversion of 319 shares of Series G Convertible Preferred Stock
|
2025-03-31 |
| 2025-04-21 | 739.26 | 8.79 | 定期报告 | 2025-03-25 |
| 2025-04-11 | 336.36 | 9.08 |
更多>>
From December 31, 2023 to December 31, 2024
Issuance of common stock for vested restricted stock units
Issuance of common stock for services
Issuance of 5,050 shares of Series F-1 Convertible Preferred Stock, net of discount and offering costs of $35,252
Issuance of 8,950 shares of Series G Convertible Preferred Stock, net of discount and offering costs of $48,559
Redemption of 1,195 shares of stock
Accelerated Conversion of 1,251 shares of Series F Convertible Preferred Stock
Accelerated Conversion of 303 shares of Series F-1 Convertible Preferred Stock
Conversion of 66 shares of Series G Convertible Preferred Stock
Modification of Series F Convertible Preferred Stock
|
2024-12-31 |
| 2024-11-01 | 275.51 | 7.30 | 定期报告 | 2024-10-18 |
| 2024-11-14 | 247.20 | 7.30 |
更多>>
From June 30, 2024 to September 30, 2024
Accelerated Conversion of 113 shares of Series F Convertible Preferred Stock
|
2024-09-30 |
| 2024-08-19 | 237.04 | 7.30 |
更多>>
From March 31, 2024 to June 30, 2024
Accelerated Conversion of 225 shares of Series F Convertible Preferred Stock
Accelerated Conversion of 88 shares of Series F Convertible Preferred Stock
|
2024-06-30 |
| 2024-06-21 | 237.04 | 未披露 | 定期报告 | 2024-06-18 |
| 2024-07-01 | 230.76 | 7.30 | 定期报告 | 2024-05-24 |
| 2024-05-15 | 230.76 | 未披露 | 定期报告 | 2024-05-12 |
| 2024-05-15 | 215.76 | 7.30 |
更多>>
From December 31, 2023 to March 31, 2024
Issuance of common stock for vested restricted stock units
Redemption of 812 shares of Series F Convertible Preferred Stock, February 1, 2024 installment of $1,429,871 paid with cash and common stock
Redemption of 383 shares of Series F Convertible Preferred Stock, January 1, 2024 installment of $1,429,871 paid with cash and common stock
Accelerated Conversion of 438 shares of Series F Convertible Preferred Stock
Accelerated Conversion of 12 shares of Series F Convertible Preferred Stock
|
2024-03-31 |
| 2024-04-01 | 215.76 | 未披露 | 定期报告 | 2024-03-29 |
| 2024-02-13 | 209.16 | 未披露 |
更多>>
1-for-30 reverse stock split. The reverse stock split will reduce the number of shares of MyMD’s common stock outstanding from 62,749,125 shares to approximately 2,091,638 shares, subject to adjustment for the rounding up of fractional shares.
|
2024-02-15 |
| 2024-02-13 | 6274.91 | 未披露 | 定期报告 | 2024-02-13 |
| 2023-11-14 | 5090.07 | 未披露 | 定期报告 | 2023-11-10 |
| 2023-11-14 | 4700.04 | 7.30 |
更多>>
From June 30, 2023 to September 30, 2023
Conversion of 1,250 shares of Series F Convertible Preferred Stock, September 1, 2023 installment of $1,429,871 paid with common stock
Conversion of 1,188 shares of Series F Convertible Preferred Stock, October 1, 2023 installment of $1,429,871 paid with common stock
Deemed Dividend for the true-up of the August 1, 2023 installment for the Series F Convertible Preferred Stock paid with common stock
Accelerated Conversion of 204 shares of Series F Convertible Preferred Stock
|
2023-09-30 |
| 2023-08-14 | 4493.04 | 未披露 | 定期报告 | 2023-08-14 |
| 2023-08-14 | 4202.71 | 8.55 |
更多>>
From March 31, 2023 to June 30, 2023
Conversion of 1,250 shares of Series F Convertible Preferred Stock, July 1, 2023 installment of $1,429,871 paid with common stock
Exercise of prepaid equity forward contract
Conversion of 1,250 shares of Series F Convertible Preferred Stock, August 1, 2023 installment of $1,429,871 paid with common stock
Issuance of common stock for vested restricted stock units
|
2023-06-30 |
| 2023-06-30 | 4079.27 | 7.30 | 定期报告 | 2023-06-21 |
| 2023-05-15 | 3960.51 | 未披露 | 定期报告 | 2023-05-12 |
| 2023-05-15 | 3947.00 | 8.80 |
更多>>
From December 31, 2022 to March 31, 2023
Issuance of 15,000 shares of Series F Convertible Preferred Stock, net of discount and offering costs of $14,087,111
|
2023-03-31 |
| 2022-11-10 | 3947.00 | 7.30 |
更多>>
From June 30, 2022 to September 30, 2022
Net proceeds from private placement of 1,411,764 common shares, net of offering costs of 449,500
|
2022-09-30 |
| 2022-08-17 | 3947.00 | 未披露 |
更多>>
1.Common Stock offered by 1,411,764 shares
2.The number of shares of common stock that will be outstanding immediately after this offering as shown above is based on 38,058,245 shares outstanding as of August 15, 2022
|
2022-08-17 |
| 2022-05-16 | 3805.82 | 7.30 |
更多>>
From December 31, 2021 to March 31, 2022
Exercise of prepaid equity forward contracts for common stock
Stock-based compensation – stock options
Stock-based compensation – restricted stock units
|
2022-03-31 |
| 2022-03-31 | 3767.31 | 7.30 |
更多>>
From December 31, 2020 to December 31, 2021
Reverse merger with Akers Biosciences Inc effective April 16, 2021
Issuance of post-merger MyMD Pharmaceutical Inc common shares at an exchange ratio of 0.7718 per pre-merger MyMD common share
Modification of the terms of 4,188,315 pre-merger MyMD stock options per the terms of the merger agreement
Exercise of per-merger MyMD stock options
Exercise of prepaid equity forward contracts for common stock
Stock based compensation for services
Exercise of warrants for common stock
|
2021-12-31 |
| 2021-11-22 | 3764.80 | 未披露 | 定期报告 | 2021-11-08 |
| 2021-11-12 | 3763.99 | 未披露 | 定期报告 | 2021-11-05 |
| 2021-11-12 | 3741.98 | 7.30 |
更多>>
From June 30, 2021 to September 30, 2021
Stock based compensation for services
Exercise of warrants for common stock
|
2021-09-30 |
| 2021-08-16 | 3737.25 | 未披露 | 定期报告 | 2021-08-16 |
| 2021-08-16 | 3735.57 | 7.30 |
更多>>
From March 31, 2021 to June 30, 2021
Exercise of prepaid equity forward contracts for common stock
Modification of the terms of 4,188,315 pre-merger MyMD stock options per the terms of the merger agreement
Reverse merger with Akers Biosciences Inc effective April 16, 2021
|
2021-06-30 |
| 2021-04-28 | 3688.00 | 7.30 | 定期报告 | 2021-04-23 |
| 2021-04-16 | 3728.22 | 未披露 |
更多>>
In connection with the Merger, Akers will effect a 1-for-2 reverse stock split of its common stock (the “Reverse Split”). Akers and MYMD expect the name changes, the Reverse Stock Split, and the Merger to become effective after-market hours on Friday, April 16, 2021. Effective with the aforementioned changes, a total of approximately 37,282,169 shares of common stock will be outstanding, with the CUSIP number changing to 62856X102.
|
2021-04-19 |
| 2021-03-23 | 1665.28 | 7.30 | 定期报告 | 2021-03-12 |
| 2021-03-01 | 1665.28 | 未披露 | 定期报告 | 2021-02-26 |
| 2021-03-01 | 1758.53 | 7.30 |
更多>>
From December 31,2019 to December 31,2020
Exercise of pre-funded warrants for common stock
Stock-based compensation – acquisition of license for preferred series “D” stock
Stock-based compensation – acquisition of license for common stock
Exercise of Series C Convertible Preferred Warrants for common stock
Exercise of Series D Convertible Preferred Shares for common stock
Registered direct offering of common stock, net of offering costs of $513,795
Registered direct offering of common stock, net of offering costs of $504,281
Registered direct offering of common stock, net of offering costs of $689,874
Private placement of common stock, net of offering costs of $1,522,694
Share-based compensation – shares issued for litigation settlements
|
2020-12-31 |
| 2020-11-16 | 885.99 | 7.30 |
更多>>
From June 30, 2020 to September 30, 2020
Exercise of Series C Convertible Preferred Warrants for common stock
Exercise of Series D Convertible Preferred Shares for common stock
Registered direct offering of common stock net of offering costs of $689,874
Share-based compensation - shares issued for litigation settlements
|
2020-09-30 |
| 2020-08-14 | 872.43 | 未披露 |
更多>>
On August 13, 2020, pursuant to a securities purchase agreement with certain institutional and accredited investors, dated August 11, 2020, the Company issued and sold in a registered direct offering (the “August Offering”) an aggregate of 1,207,744 shares of its common stock at an offering price of $5.67 per share, for gross and net proceeds of approximately $6.8 million and $6.2 million, respectively. The Company issued to the placement agent or its designees warrants to purchase up to 96,620 shares of common stock at an exercise price of $7.0875 as compensation in connection with the August Offering.
|
2020-08-13 |
| 2020-08-13 | 746.65 | 未披露 | 定期报告 | 2020-08-11 |
| 2020-08-14 | 612.50 | 20.86 |
更多>>
From March 31, 2020 to June 30, 2020
Conversion of Series D Convertible Preferred Shares for common stock
Registered direct offering of common stock net of offering costs of $513,795
Registered direct offering of common stock net of offering costs of $504,281
Exercise of prepaid equity forward contracts for common stock
Exercise of Series C Convertible Preferred warrants for common stock
|
2020-06-30 |
| 2020-05-19 | 612.23 | 未披露 |
更多>>
Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced the closing of its previously announced registered direct offering of an aggregate of 1,366,856 shares of the Company’s common stock, at a purchase price of $3.53 per share priced at-the-market under Nasdaq rules.
|
2020-05-18 |
| 2020-05-18 | 475.54 | 未披露 | 定期报告 | 2020-05-13 |
| 2020-05-15 | 291.52 | 21.14 |
更多>>
From December 31, 2019 to March 31, 2020
Shares issued for the purchase of license
Exercise of prepaid equity forward contracts for common stock
|
2020-03-31 |
| 2020-03-25 | 270.02 | 未披露 | 定期报告 | 2020-03-24 |
| 2020-03-25 | 173.88 | 未披露 |
更多>>
From December 31, 2018 to December 31, 2019
Public offering - common stock, net of offering costs of $306,222
Issuance of stock grants to officer
Issuance of common stock to vendor for services
Exercise of prepaid equity forward contracts for common stock
|
2019-12-31 |
| 2019-12-04 | 52.33 | 未披露 | 定期报告 | 2019-12-04 |
| 2019-11-29 | 52.17 | 未披露 | 定期报告 | 2019-11-29 |
| 2019-11-25 | 52.17 | 未披露 |
更多>>
Akers Biosciences, Inc. (NASDAQ: AKER), (“Akers Bio” or the "Company"), a developer of rapid health information technologies, today announced that effective at 8:00 a.m. eastern standard time on Monday, November 25, 2019, the Company will effect a reverse stock split of its issued and outstanding common stock of no par value at a ratio of one (1) share of common stock for every twenty four (24) shares of common stock.
|
2019-11-25 |
| 2019-11-01 | 1252.02 | 未披露 | 定期报告 | 2019-11-01 |
| 2019-11-14 | 1251.65 | 未披露 |
更多>>
From June 30, 2019 to September 30, 2019
Issuance of stock grants to key employees
|
2019-09-30 |
| 2019-08-14 | 1251.27 | 未披露 | 定期报告 | 2019-08-09 |
| 2019-08-14 | 1250.90 | 未披露 |
更多>>
From March 31, 2019 to June 30, 2019
Issuance of unrestricted stock to a key employee
|
2019-06-30 |
| 2019-05-20 | 1249.77 | 未披露 |
更多>>
From December 31, 2018 to March 31, 2019
Issuance of stock grants to key employees
|
2019-03-31 |
| 2019-04-01 | 1248.27 | 未披露 |
更多>>
From December 31, 2017 to December 31, 2018
Exercise of warrants for common stock
Conversion of preferred stock to common stock
Private offering of common stock, net of offering costs of $50,000
Issuance of stock grants to key employees
|
2018-12-31 |
| 2018-11-09 | 1247.40 | 未披露 |
更多>>
On November 7, 2018, effective as of November 8, 2018, Akers Biosciences, Inc. (the “Company”) filed a Certificate of Amendment (the “Certificate of Amendment”) to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of New Jersey to effect a reverse stock split of its common stock at a ratio of eight-for-one (8-for-1). As a result of the reverse stock split, there are approximately 12,474,028 shares of common stock outstanding.
|
2018-11-08 |
| 2018-11-14 | 9963.03 | 未披露 | 定期报告 | 2018-11-07 |
| 2018-08-14 | 9410.63 | 未披露 |
更多>>
From December 31, 2017 to June 30, 2018
Exercise of warrants for common stock
Conversion of preferred stock to common stock
Issuance of restricted stock to key employees
|
2018-06-30 |
| 2018-07-13 | 8643.76 | 未披露 |
更多>>
From December 31, 2017 to March 31, 2018
Conversion of preferred stock to common stock
Exercise of warrants for common stock
Issuance of stock grants to key employees
Issuance of non-qualified stock options to key employees
Issuance of restricted stock for services for non-employees
|
2018-03-31 |
| 2018-04-03 | 8197.40 | 未披露 | 定期报告 | 2018-03-15 |
| 2018-04-03 | 4422.06 | 0.18 |
更多>>
from December 31, 2016 to December 31, 2017
Public offering of common and preferred stock, net of offering costs of $834,414
Conversion of preferred stock to common stock
Share register adjustment
Public offering of common stock, net of offering costs of $494,406
Private offering of common stock, net of offering costs of $267,443
Warrant Modification
Exercise of warrants for common stock
Amortization of deferred compensation
Issuance of stock grants to officers
Issuance of stock grants to key employees
Issuance of non-qualified stock options to key employees
Issuance of non-qualified stock options for services to non-employees
Issuance of restricted stock for services for non-employees
|
2017-12-31 |
| 2017-11-14 | 992.06 | 未披露 | 定期报告 | 2017-11-10 |
| 2017-08-14 | 890.12 | 未披露 |
更多>>
From December 31, 2016 to June 30 2017
Public offering of common stock, net of offering costs of $494,406
Private offering of common stock, net of offering costs of $267,443
Exercise of warrants for common stock
Issuance of restricted stock for services to non-employees
|
2017-06-30 |
| 2017-06-26 | 889.12 | 未披露 | 定期报告 | 2017-06-23 |
| 2017-05-15 | 889.51 | 未披露 | 定期报告 | 2017-05-15 |
| 2017-05-15 | 885.37 | 未披露 |
更多>>
From December 31, 2016 to March 31, 2017
Public offering of common stock, net of offering costs of $455,356
Private offering of common stock, net of offering costs of $266,943
Exercise of warrants for common stock
|
2017-03-31 |
| 2016-08-11 | 545.25 | 未披露 |
更多>>
From December 31, 2015 to June 30, 2016
Issuance of Restricted Stock to Officers
|
2016-06-30 |
| 2016-03-30 | 542.50 | 未披露 |
更多>>
from December 31, 2014 to December 31, 2015
Issuance of Restricted Common Stock for Directors & Officers
Issuance of Restricted Common Stock for Key Employees
Issuance of Restricted Common Stock for services
|
2015-12-31 |
| 2015-03-23 | 514.48 | 未披露 | 定期报告 | 2015-03-23 |
| 2014-01-23 | 489.48 | 未披露 | 定期报告 | 2014-01-23 |
| 2013-11-18 | 179.18 | 1000.00 |
更多>>
from December 31, 2012 to November 25, 2013
Issuance of shares
On November 18, 2013 the Company announced a 1-for-156 reverse stock split (the “Reverse Stock Split”). Upon effectiveness of the Reverse Stock Split on November 22, 2013, every 156 shares of outstanding common stock shall be decreased to one share of common stock.
|
2013-11-25 |
| 2013-08-07 | 27951.57 | 1000.00 |
更多>>
from December 31, 2012 to June 30, 2013
Sale of common shares
|
2013-06-30 |
From March 31,2026 to June 30,2026
Stock based compensation - Restricted Stock Awards
Stock-based Compensation - Restricted Stock Units
Preferred Stock Dividends and Dividend Adjustments
From December 31, 2025 to March 31, 2026
Common Stock Warrant Exercises
Stock based compensation – Restricted Stock Units
From December 31, 2024 to December 31, 2025
True-up for par value related to reverse stock split
Issuance of Series G Convertible Preferred Stock in Lieu of Dividends
Issuance of 7,000 shares of Series H Convertible Preferred Stock, net of discount and offering costs of $609,578
Issuance of 747,362 shares of Series I Convertible Preferred Stock
Conversion of 1,946 shares of Series G Convertible Preferred Stock
Conversions of Series H Convertible Preferred Stock
Conversions of Series I Convertible Preferred Stock
Conversion of Series F and F1 Convertible Preferred Stock
Issuance of Common Stock for Services Provided
Issuance of Common Stock as Series H Dividends
Common Stock Warrant Exercises
From June 30, 2025 to September 30, 2025
Accelerated Conversion of 4,382 shares of Series F Convertible Preferred Stock
Accelerated Conversion of 2,065 shares of Series F-1 Convertible Preferred Stock
Conversion of 606 shares of Series G Convertible Preferred Stock
Issuance of Series G Convertible Preferred Stock
Issuance of 7,000 shares of Series H Convertible Preferred Stock, net of discount and offering costs of $609,578
Issuance of 747,362 shares of Series I Convertible Preferred Stock
Proceeds from the exercise of common stock warrants
a reverse stock split of the Company's common stock at a ratio of 1 post-split share for every 100 pre-split shares
From March 31, 2025 to June 30, 2025
Accelerated Conversion of 24 shares of Series F Convertible Preferred Stock
Accelerated Conversion of 1,748 shares of Series F-1 Convertible Preferred Stock
Conversion of 1,021 shares of Series G Convertible Preferred Stock
From December 31, 2024 to March 31, 2025
Accelerated Conversion of 371 shares of Series F Convertible Preferred StockAccelerated Conversion of 2001 shares of Series F-1 Convertible Preferred Stock
Conversion of 319 shares of Series G Convertible Preferred Stock
From December 31, 2023 to December 31, 2024
Issuance of common stock for vested restricted stock units
Issuance of common stock for services
Issuance of 5,050 shares of Series F-1 Convertible Preferred Stock, net of discount and offering costs of $35,252
Issuance of 8,950 shares of Series G Convertible Preferred Stock, net of discount and offering costs of $48,559
Redemption of 1,195 shares of stock
Accelerated Conversion of 1,251 shares of Series F Convertible Preferred Stock
Accelerated Conversion of 303 shares of Series F-1 Convertible Preferred Stock
Conversion of 66 shares of Series G Convertible Preferred Stock
Modification of Series F Convertible Preferred Stock
From June 30, 2024 to September 30, 2024
Accelerated Conversion of 113 shares of Series F Convertible Preferred Stock
From March 31, 2024 to June 30, 2024
Accelerated Conversion of 225 shares of Series F Convertible Preferred Stock
Accelerated Conversion of 88 shares of Series F Convertible Preferred Stock
From December 31, 2023 to March 31, 2024
Issuance of common stock for vested restricted stock units
Redemption of 812 shares of Series F Convertible Preferred Stock, February 1, 2024 installment of $1,429,871 paid with cash and common stock
Redemption of 383 shares of Series F Convertible Preferred Stock, January 1, 2024 installment of $1,429,871 paid with cash and common stock
Accelerated Conversion of 438 shares of Series F Convertible Preferred Stock
Accelerated Conversion of 12 shares of Series F Convertible Preferred Stock
1-for-30 reverse stock split. The reverse stock split will reduce the number of shares of MyMD’s common stock outstanding from 62,749,125 shares to approximately 2,091,638 shares, subject to adjustment for the rounding up of fractional shares.
From June 30, 2023 to September 30, 2023
Conversion of 1,250 shares of Series F Convertible Preferred Stock, September 1, 2023 installment of $1,429,871 paid with common stock
Conversion of 1,188 shares of Series F Convertible Preferred Stock, October 1, 2023 installment of $1,429,871 paid with common stock
Deemed Dividend for the true-up of the August 1, 2023 installment for the Series F Convertible Preferred Stock paid with common stock
Accelerated Conversion of 204 shares of Series F Convertible Preferred Stock
From March 31, 2023 to June 30, 2023
Conversion of 1,250 shares of Series F Convertible Preferred Stock, July 1, 2023 installment of $1,429,871 paid with common stock
Exercise of prepaid equity forward contract
Conversion of 1,250 shares of Series F Convertible Preferred Stock, August 1, 2023 installment of $1,429,871 paid with common stock
Issuance of common stock for vested restricted stock units
From December 31, 2022 to March 31, 2023
Issuance of 15,000 shares of Series F Convertible Preferred Stock, net of discount and offering costs of $14,087,111
From June 30, 2022 to September 30, 2022
Net proceeds from private placement of 1,411,764 common shares, net of offering costs of 449,500
1.Common Stock offered by 1,411,764 shares
2.The number of shares of common stock that will be outstanding immediately after this offering as shown above is based on 38,058,245 shares outstanding as of August 15, 2022
From December 31, 2021 to March 31, 2022
Exercise of prepaid equity forward contracts for common stock
Stock-based compensation – stock options
Stock-based compensation – restricted stock units
From December 31, 2020 to December 31, 2021
Reverse merger with Akers Biosciences Inc effective April 16, 2021
Issuance of post-merger MyMD Pharmaceutical Inc common shares at an exchange ratio of 0.7718 per pre-merger MyMD common share
Modification of the terms of 4,188,315 pre-merger MyMD stock options per the terms of the merger agreement
Exercise of per-merger MyMD stock options
Exercise of prepaid equity forward contracts for common stock
Stock based compensation for services
Exercise of warrants for common stock
From June 30, 2021 to September 30, 2021
Stock based compensation for services
Exercise of warrants for common stock
From March 31, 2021 to June 30, 2021
Exercise of prepaid equity forward contracts for common stock
Modification of the terms of 4,188,315 pre-merger MyMD stock options per the terms of the merger agreement
Reverse merger with Akers Biosciences Inc effective April 16, 2021
In connection with the Merger, Akers will effect a 1-for-2 reverse stock split of its common stock (the “Reverse Split”). Akers and MYMD expect the name changes, the Reverse Stock Split, and the Merger to become effective after-market hours on Friday, April 16, 2021. Effective with the aforementioned changes, a total of approximately 37,282,169 shares of common stock will be outstanding, with the CUSIP number changing to 62856X102.
From December 31,2019 to December 31,2020
Exercise of pre-funded warrants for common stock
Stock-based compensation – acquisition of license for preferred series “D” stock
Stock-based compensation – acquisition of license for common stock
Exercise of Series C Convertible Preferred Warrants for common stock
Exercise of Series D Convertible Preferred Shares for common stock
Registered direct offering of common stock, net of offering costs of $513,795
Registered direct offering of common stock, net of offering costs of $504,281
Registered direct offering of common stock, net of offering costs of $689,874
Private placement of common stock, net of offering costs of $1,522,694
Share-based compensation – shares issued for litigation settlements
From June 30, 2020 to September 30, 2020
Exercise of Series C Convertible Preferred Warrants for common stock
Exercise of Series D Convertible Preferred Shares for common stock
Registered direct offering of common stock net of offering costs of $689,874
Share-based compensation - shares issued for litigation settlements
On August 13, 2020, pursuant to a securities purchase agreement with certain institutional and accredited investors, dated August 11, 2020, the Company issued and sold in a registered direct offering (the “August Offering”) an aggregate of 1,207,744 shares of its common stock at an offering price of $5.67 per share, for gross and net proceeds of approximately $6.8 million and $6.2 million, respectively. The Company issued to the placement agent or its designees warrants to purchase up to 96,620 shares of common stock at an exercise price of $7.0875 as compensation in connection with the August Offering.
From March 31, 2020 to June 30, 2020
Conversion of Series D Convertible Preferred Shares for common stock
Registered direct offering of common stock net of offering costs of $513,795
Registered direct offering of common stock net of offering costs of $504,281
Exercise of prepaid equity forward contracts for common stock
Exercise of Series C Convertible Preferred warrants for common stock
Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced the closing of its previously announced registered direct offering of an aggregate of 1,366,856 shares of the Company’s common stock, at a purchase price of $3.53 per share priced at-the-market under Nasdaq rules.
From December 31, 2019 to March 31, 2020
Shares issued for the purchase of license
Exercise of prepaid equity forward contracts for common stock
From December 31, 2018 to December 31, 2019
Public offering - common stock, net of offering costs of $306,222
Issuance of stock grants to officer
Issuance of common stock to vendor for services
Exercise of prepaid equity forward contracts for common stock
Akers Biosciences, Inc. (NASDAQ: AKER), (“Akers Bio” or the "Company"), a developer of rapid health information technologies, today announced that effective at 8:00 a.m. eastern standard time on Monday, November 25, 2019, the Company will effect a reverse stock split of its issued and outstanding common stock of no par value at a ratio of one (1) share of common stock for every twenty four (24) shares of common stock.
From June 30, 2019 to September 30, 2019
Issuance of stock grants to key employees
From March 31, 2019 to June 30, 2019
Issuance of unrestricted stock to a key employee
From December 31, 2018 to March 31, 2019
Issuance of stock grants to key employees
From December 31, 2017 to December 31, 2018
Exercise of warrants for common stock
Conversion of preferred stock to common stock
Private offering of common stock, net of offering costs of $50,000
Issuance of stock grants to key employees
On November 7, 2018, effective as of November 8, 2018, Akers Biosciences, Inc. (the “Company”) filed a Certificate of Amendment (the “Certificate of Amendment”) to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of New Jersey to effect a reverse stock split of its common stock at a ratio of eight-for-one (8-for-1). As a result of the reverse stock split, there are approximately 12,474,028 shares of common stock outstanding.
From December 31, 2017 to June 30, 2018
Exercise of warrants for common stock
Conversion of preferred stock to common stock
Issuance of restricted stock to key employees
From December 31, 2017 to March 31, 2018
Conversion of preferred stock to common stock
Exercise of warrants for common stock
Issuance of stock grants to key employees
Issuance of non-qualified stock options to key employees
Issuance of restricted stock for services for non-employees
from December 31, 2016 to December 31, 2017
Public offering of common and preferred stock, net of offering costs of $834,414
Conversion of preferred stock to common stock
Share register adjustment
Public offering of common stock, net of offering costs of $494,406
Private offering of common stock, net of offering costs of $267,443
Warrant Modification
Exercise of warrants for common stock
Amortization of deferred compensation
Issuance of stock grants to officers
Issuance of stock grants to key employees
Issuance of non-qualified stock options to key employees
Issuance of non-qualified stock options for services to non-employees
Issuance of restricted stock for services for non-employees
From December 31, 2016 to June 30 2017
Public offering of common stock, net of offering costs of $494,406
Private offering of common stock, net of offering costs of $267,443
Exercise of warrants for common stock
Issuance of restricted stock for services to non-employees
From December 31, 2016 to March 31, 2017
Public offering of common stock, net of offering costs of $455,356
Private offering of common stock, net of offering costs of $266,943
Exercise of warrants for common stock
From December 31, 2015 to June 30, 2016
Issuance of Restricted Stock to Officers
from December 31, 2014 to December 31, 2015
Issuance of Restricted Common Stock for Directors & Officers
Issuance of Restricted Common Stock for Key Employees
Issuance of Restricted Common Stock for services
from December 31, 2012 to November 25, 2013
Issuance of shares
On November 18, 2013 the Company announced a 1-for-156 reverse stock split (the “Reverse Stock Split”). Upon effectiveness of the Reverse Stock Split on November 22, 2013, every 156 shares of outstanding common stock shall be decreased to one share of common stock.
from December 31, 2012 to June 30, 2013
Sale of common shares